Compounding Clarity Act of 2013

Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54) H.R 4069 - Ensuring Patient Access and Effective Drug Enforcement Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

Monitor and lobby legislation and regulation relating to compounding pharmacies. Bills include: H.R. 3204, S. 959, and H.R. 3089.

Client expense: Not reported · Firm income: $20,000

Government targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.3089 - Compounding Clarity Act H.R.3528 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 S.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013

Client expense: $291,064 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - implementation issues related to reauthorization of user fees for prescription drug, medical device, and biologics approval - Regulation of online pharmacies and prescription painkillers. Prescriber Education and CME TrainingH.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013 - drug shortage issues. S. 959 - Pharmaceutical Compounding Quality and Accountability Act - drug shortage issues, prescriber education and CME training. H.R. 2186 - Valid Compounding Act - drug shortage issues H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013- drug shortage issues H.R. 3089 - the Compounding Clarity Act - drug shortage issues. Public Law 113-54 - the Drug Quality and Security Act - drug shortage issues. FDA and HHS recommendations for rescheduling certain drugs. H.R. 4800/S. 2389, Agriculture FDA Appropriations for FY 2015

Client expense: Not reported · Firm income: $75,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Monitor and lobby legislation and regulation relating to compounding pharmacies. Bills include: H.R. 3204, S. 959, and H.R. 3089.

Client expense: Not reported · Firm income: $20,000

Government targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54) H.R 4069 - Ensuring Patient Access and Effective Drug Enforcement Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

H.R.3089 - Compounding Clarity Act H.R.3528 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 S.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013

Client expense: $646,873 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 To amend the Controlled Substances Act to make any substance containinghydrocodone a schedule II drug H.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 Safe Prescribing Act S. 959 Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 Compounding Clarity Act H.R. 3204 Drug Quality and Security Act (Public Law 113-54)

Client expense: $117,584 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - implementation issues related to reauthorization of user fees for prescription drug, medical device, and biologics approval - Regulation of online pharmacies and prescription painkillers. Prescriber Education and CME TrainingH.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013 - drug shortage issues. S. 959 - Pharmaceutical Compounding Quality and Accountability Act - drug shortage issues, prescriber education and CME training. H.R. 2186 - Valid Compounding Act - drug shortage issues H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013- drug shortage issues H.R. 3089 - the Compounding Clarity Act - drug shortage issues. Public Law 113-54 - the Drug Quality and Security Act - drug shortage issues. FDA and HHS recommendations for rescheduling certain drugs.

Client expense: Not reported · Firm income: $75,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Monitor and lobby legislation and regulation relating to compounding pharmacies. Bills include: H.R. 3204, S. 959, and H.R. 3089.

Client expense: Not reported · Firm income: $20,000

Government targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Pharmacy Compounding, S. 959- Pharmaceutical Compounding and Quality and Accountability Act, H.R. 3089- Compounding Clarity Act of 2013, H.R. 3204- Drug Quality and Security Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.3089-Compounding Clarity Act H.R.3528-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 S.1323-Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013

Client expense: $538,613 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54) H.R 4069 - Ensuring Patient Access and Effective Drug Enforcement Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues relating to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $28,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues related to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S. 959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) Issues relating to implementation of the Compounding Quality Act

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 Safe Prescribing Act S. 959 Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 Compounding Clarity Act H.R. 3204 Drug Quality and Security Act (Public Law 113-54)

Client expense: $101,617 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - implementation issues related to reauthorization of user fees for prescription drug, medical device, and biologics approval - Regulation of online pharmacies and prescription painkillers. Prescriber Education and CME TrainingH.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013 - drug shortage issues. S. 959 - Pharmaceutical Compounding Quality and Accountability Act - drug shortage issues, prescriber education and CME training. H.R. 2186 - Valid Compounding Act - drug shortage issues H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013- drug shortage issues H.R. 3089 - the Compounding Clarity Act - drug shortage issues. H.R. 3204 - the Drug Quality and Security Act - drug shortage issues. FDA and HHS recommendations for rescheduling certain drugs.

Client expense: Not reported · Firm income: $75,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Pharmacy Compounding, S. 959- Pharmaceutical Compounding Quality and Accountability Act, H.R. 3089- Compounding Clarity Act, H.R. 3204- Drug Quality and Security Act, TRICARE Drug Coverage Policy, H.R. 3304- The National Defense Authorization Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor and lobby legislation and regulation relating to compounding pharmacies. Bills include: H.R. 3204, S. 959, and H.R. 3089.

Client expense: Not reported · Firm income: $20,000

Government targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Patient Protection and Affordable Care Act Implementation, S. 959- Pharmaceutical Quality and Accountability Act, H.R. 3089- Compounding Clarity Act of 2013, H.R. 3204- Drug Quality and Security Act

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy Compounding, S. 959- Pharmaceutical Compounding Quality and Accountability Act, H.R. 3089- Compounding Clarity Act of 2013, H.R. 3204- Drug Quality and Security Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to track and trace. H.R. 3204, The Drug Quality and Security Act, S. 959, The Pharmaceutical Quality, Security and Accountability Act, H. R. 3089, The Compounding Clarity Act of 2013, as they relate to drug supply chain security.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of Health Care Reform, Implementation of Generic Biologics, Counterfeit Drugs/Import Safety, Prescription Drug Importation/Re-Importation, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar NamingH.R.486 - Stop Tampering of Prescription Pills Act of 2013 H.R.1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug. H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013 H.R.1958 - Gray Market Drug Reform and Transparency Act of 2013 H.R.2186 - VALID Compounding Act of 2013 H.R. 2725 FDA Safety over Sequestration Act H.R. 3019 SAFE Compounded Drugs Act H.R. 3089 Compounding Clarity Act of 2013 H.R. 3204 Drug Quality and Security Act H.R. 3709 Protecting Consumers Access to Generic Drugs Act of 2013 H. Con. Res. 25 - Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023 H Res - 161 Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs S.214 - Preserve Access to Affordable Generics Act S.504 - Fair and Immediate Release of Generic Drugs Act S.621 - Safe Prescribing Act of 2013 S 957 - Drug Supply Chain Security Act S 959 - Pharmaceutical Quality, Security, and Accountability Act

Client expense: $604,408 · Firm income: Not reported

Government targets: Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

H.R. 3204, The Drug Quality and Security Act, S. 959, The Pharmaceutical Quality, Security and Accountability Act, H.R. 3089, The Compounding Clarity Act of 2013, as they relate to drug supply chain security and safe pharmaceutical compounding; H.R. 698, the HIV Organ Policy Equity Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 855 - Optometric Equity in Medicaid Act, Federal mandates for Medicaid of optometric medical & surgical coverage, all sections SGR - Medicare Physician Payment Reform H.R. 702, Access to Frontline Health Care Act, all sectionsH.R. 1427, Truth in Health Marketing Act, all sections H.R. 351, Protecting Seniors Access to Medicare Act, all sections S. 351, Protecting Seniors Access to Medicare Act, all sections P.L. 111-192, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010, all sections related to physicians and vision P.L. 111-148 Affordable Care Act, modifications: 1. Reducing regulatory/costly burdens on medical practices - relief from regulatory penalties 2. Preserving patient access to office ancillary testing services 3. Essential Benefits - Children's Vision 4. Independent Payment Advisory Board H.R. 920, National Health Service Corps Improvement Act H.R. 1331, Electronic Health Records Improvement Act S. 959, Pharmaceutical Compounding Quality and Accountability Act, all sections H.R. 3089, Compounding Clarity Act, all sections H.R. 3204, Drug Quality & Security Act, all sections

Client expense: $190,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 To amend the Controlled Substances Act to make any substance containinghydrocodone a schedule II drug H.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 Safe Prescribing Act S. 959 Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 Compounding Clarity Act H.R. 3204 Drug Quality and Security Act (Public Law 113-54)

Client expense: $101,618 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Monitor and advocate regarding pharmacy issues impacting Long Term Care and Post Acute Care providers and patients. Amend the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug, H.R. 1285/S.621; Stop Oxy Abuse Act of 2013, H.R. 1366; The Pharmaceutical Quality, Security, and Accountability Act, S. 959, H.R. 3089

Client expense: $95,997 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54)

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54)

Client expense: Not reported · Firm income: $15,625

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

S.959, Pharmaceutical Quality, Security, and Accountability Act; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.3089 - Compounding Clarity Act H.R.3204 - Drug Quality and Security Act H.R.3528 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 S.959 - Pharmaceutical Compounding Quality and Accountability ActS.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013

Client expense: $537,439 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S. 959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204)

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204)

Client expense: Not reported · Firm income: $9,575

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204)

Client expense: Not reported · Firm income: $11,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE